Literature DB >> 1905058

New York State's two-dose schedule for measles immunization.

G S Birkhead1, D L Morse, I J Mills, L F Novick.   

Abstract

In April 1989, New York became the first State in the United States to adopt a two-dose schedule for routine measles immunization. Although a two-dose schedule had been under discussion for the previous 10 years, this policy change was finally prompted in New York State by widespread measles outbreaks in 1989 among college and high school students who had been appropriately vaccinated with a single dose of measles vaccine. These outbreaks affected 21 college and secondary school campuses with 91 cases of measles and led to the administration of 53,093 doses of vaccine at a cost in excess of $859,000 for vaccine alone. In addition, there were major disruptions of intercollegiate athletic and scholastic events and physician and public confusion over the different recommendations for "outbreak" versus "routine" measles immunization. In response, the New York State Department of Health adopted a policy of two doses of measles vaccine required for entrance into kindergarten and college beginning in the fall of 1990. This report describes the data and process that were used in reaching this policy decision.

Entities:  

Mesh:

Year:  1991        PMID: 1905058      PMCID: PMC1580250     

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  21 in total

1.  Mild measles and secondary vaccine failure during a sustained outbreak in a highly vaccinated population.

Authors:  M B Edmonson; D G Addiss; J T McPherson; J L Berg; S R Circo; J P Davis
Journal:  JAMA       Date:  1990-05-09       Impact factor: 56.272

Review 2.  Duration of live measles vaccine-induced immunity.

Authors:  L E Markowitz; S R Preblud; P E Fine; W A Orenstein
Journal:  Pediatr Infect Dis J       Date:  1990-02       Impact factor: 2.129

3.  Measles outbreak in a vaccinated school population: epidemiology, chains of transmission and the role of vaccine failures.

Authors:  B M Nkowane; S W Bart; W A Orenstein; M Baltier
Journal:  Am J Public Health       Date:  1987-04       Impact factor: 9.308

Review 4.  Measles and rubella in the United States.

Authors:  H W Hethcote
Journal:  Am J Epidemiol       Date:  1983-01       Impact factor: 4.897

5.  The future of measles in highly immunized populations. A modeling approach.

Authors:  D L Levy
Journal:  Am J Epidemiol       Date:  1984-07       Impact factor: 4.897

6.  Risk factors for measles vaccine failure among immunized students.

Authors:  H F Hull; J M Montes; P C Hays; R L Lucero
Journal:  Pediatrics       Date:  1985-10       Impact factor: 7.124

7.  Control of measles in Czechoslovakia (CSSR).

Authors:  J Sejda
Journal:  Rev Infect Dis       Date:  1983 May-Jun

8.  A persistent outbreak of measles despite appropriate prevention and control measures.

Authors:  R M Davis; E D Whitman; W A Orenstein; S R Preblud; L E Markowitz; A R Hinman
Journal:  Am J Epidemiol       Date:  1987-09       Impact factor: 4.897

9.  Directly transmitted infections diseases: control by vaccination.

Authors:  R M Anderson; R M May
Journal:  Science       Date:  1982-02-26       Impact factor: 47.728

10.  Further-attenuated measles vaccine: characteristics and use.

Authors:  S Krugman
Journal:  Rev Infect Dis       Date:  1983 May-Jun
View more
  3 in total

1.  Measles outbreak at a university without a two-dose immunization requirement.

Authors:  W A Christmas; M Mamolen; F E James
Journal:  West J Med       Date:  1998-06

2.  Outbreak of measles in a teenage school population: the need to immunize susceptible adolescents.

Authors:  D Morse; M O'Shea; G Hamilton; N Soltanpoor; G Leece; E Miller; D Brown
Journal:  Epidemiol Infect       Date:  1994-10       Impact factor: 2.451

3.  Public health response to a measles outbreak on a university campus in Australia, 2015.

Authors:  J Smith; S Banu; M Young; D Francis; K Langfeldt; K Jarvinen
Journal:  Epidemiol Infect       Date:  2018-01-17       Impact factor: 4.434

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.